Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01087437|
Recruitment Status : Unknown
Verified March 2014 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : March 16, 2010
Last Update Posted : April 1, 2014
BACKGROUND: Distraction osteogenesis, the gradual lengthening of bones, is performed in order to equalize leg length discrepancy and correct skeletal deformities or to achieve greater height in short stature people. The femur and tibia are the bones most frequently lengthened. The surgery is currently performed at Hadassah Medical Center routinely by the pediatric orthopedic team utilizing a variety of external fixation devices.
The procedure involves application of an external fixation device to the bone, creation of an osteotomy and gradual, controlled distraction of the bone fragments On the last week of the distraction phase and every month thereafter, patients will be provided with a monthly supply of gastrolith calcium in a sealed container (65 capsules of 500 mg each, provided by Amorphical). Starting on the first day of the last week of the distraction phase, during the entire consolidation phase until the external fixator is removed; adults will orally consume two (2) 500 mg capsules a day (total of 1 gr of gastrolith calcium). Children will be given 25 mg calcium per kg body weight up to the daily adult dose of 1000mg .
|Condition or disease||Intervention/treatment||Phase|
|Skeletal Deformities Leg Length Discrepancy||Dietary Supplement: gastrolith calcium||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Study Start Date :||January 2011|
|Experimental: gastrolith calcium treatment||
Dietary Supplement: gastrolith calcium
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01087437
|Contact: Ron Lamdan, M.Demail@example.com|
|Hadassah Medical Organizaton||Recruiting|
|Contact: Arik Tzukert, DMD 00 972 2 6776095 firstname.lastname@example.org|